APPENDIX 25: EXCLUDED STUDIES

Excluded studies table 2
Studies that were ongoing or awaiting assessment 4
References to excluded studies 5

Abbreviations

CBT	cognitive behavioural therapy
N	number of participants
RCT	randomised controlled trial
SD	standard deviation

Excluded studies table

STUDY ID (STUDY CITATION)	REASON FOR EXCLUSION
Studies of adults	
ALLSOPP1984 (Allsopp, 1984)	Medication for mixed population (N = 33 with agoraphobia or social phobia).
BUTLER1984 (Butler et al., 1984)	No usable data (outcomes not reported in a format that can be extracted for meta-analysis).
CASSIN2011 (Cassin & Rector, 2011)	Not a bona fide therapy.
CLARK1991 (Clark & Agras, 1991)	Not an eligible intervention (buspirone).
DOGAHEH2011 (Dogaheh et al., 2011)	No usable data (study compares group and individual CBT, but only the Brief Fear of Negative Evaluation Scale is reported as a measure of social anxiety).
DONAHUE2009 (Donahue et al., 2009)	Single dose of quetiapine.
EMMELKAMP1985 (Emmelkamp et al., 1985)	No usable data (paper reports means but not SDs; SDs were not imputed to connect rational emotive therapy and self-instructional training to the network).
FURMARK2005 (Furmark et al., 2005)	Medication (NK1A) not used in clinical practice.
HEIDEMAN2008 (Heideman, 2008)	Intervention for social anxiety and alcohol misuse reporting no usable data for symptoms of social anxiety.
HOFMANN2004 (Hofmann, 2004)	No usable data (compares two types of group therapy with waitlist; paper reports mediation analyses, but not main effects for each intervention).
JOHNSTON2011 (Johnston et al., 2011)	No usable data (outcomes collapsed across social anxiety and other diagnostic groups).
KATZELNICK1995 (Katzelnick et al., 1995)	No usable data (outcomes reported only after crossover).
KOBAK2005 (Kobak et al., 2005)	Complementary therapy (St John's wort).
MARKS2004 (Marks et al., 2004)	Computerised therapy for mixed population. Disaggregated data not available.
MERSCH1995 (Mersch, 1995)	No usable data (waitlist group were assigned after the first phase of the study; data from two treatments merged for comparison with waitlist).
MORTBERG2006 (Mortberg et al., 2006)	No usable data (reports F-tests only for significant interactions only, so these were not extracted).
NEUBAUER2013 (Neubauer et al., 2013)	Not an eligible intervention (cognitive bias modification).
NORTON2012 (Norton & Barrera, 2012)	No usable data. Although primary diagnosis was not related to improvement with a transdiagnostic intervention (n = 12) or a diagnosis-specific intervention (n = 13), change on the measure of social anxiety non-significantly favoured the specific intervention.
RANDALL2001 (Randall et al., 2001)	Intervention for social anxiety and alcohol misuse reporting no usable data for symptoms of social anxiety.
RAVINDRAN2009 (Ravindran et al., 2009)	Medication (atomoxetine) not used in clinical practice.
SCHNEIDER2005 (Schneider et al., 2005)	Computerised therapy for mixed population (N = 24 with primary social anxiety disorder). Disaggregated data not available.
SOLYOM1981 (Solyom, 1981)	Medication for mixed population (N = 40 with agoraphobia or social phobia).
TAUSCHER2010 (Tauscher et al., 2010)	Not an eligible intervention (NK1A).
TAYLOR1997 (Taylor et al., 1997)	Not an eligible intervention (compared exposure with or without cognitive restructuring, but explicitly *not* as restructuring is used in clinical practice).
TAYLOR2010 (Taylor & Alden, 2010)	Not a bona fide therapy.
TURNER1994 (Turner et al., 1994)	Not an eligible intervention (short-term study of a beta-blocker).

TYRER1973 (Tyrer et al., 1973)	Medication for mixed population (N = 15 with social anxiety disorder).
VANAMERINGEN2007 (Van Ameringen et al., 2007)	Medication (nefazodone) not licensed in the UK. Compared only with placebo.
VAN-VLIET1997 (Van Vliet, 1997)	Not an eligible intervention (buspirone).
VERSIANI1997 (Versiani, 1997)	Medication (bromazepam) not licensed in the UK. Compared only with placebo.
ZHANG2000 (Zhang et al., 2000)	Not a bona fide therapy.
Studies of children and young people	
BARRETT1996 (Barrett et al., 1996)	Mixed population randomised by school (N = 19 primary social anxiety disorder across three groups).
BERNSTEIN2005 (Bernstein et al., 2005)	Mixed population randomised by school (N = 12 with primary social anxiety disorder).
BODDEN2008 (Bodden et al., 2008)	Mixed population (N = 41 with primary with social anxiety disorder).
HIRSHFELD-BECKER2010 (Hirshfeld-Becker et al., 2010)	Mixed population (unclear how many had primary social anxiety disorder).
KENDALL2008 (Kendall et al., 2008)	Mixed population. Disaggregated data not available.
KENNEDY2009 (Kennedy et al., 2009)	Too young (preschool).
LIBER2008 (Liber et al., 2008)	Mixed population (N = 22 with primary with social anxiety disorder).
MANASSIS2002 (Manassis et al., 2002)	Mixed population (N = 5 with primary social anxiety disorder).
OLIVARES2002 (Garcia-Lopez et al., 2002;Olivares et al., 2002)	Not an RCT.
SHORTT2001 (Shortt et al., 2001)	Mixed population (N = 10 with primary social anxiety disorder).
SILVERMAN1999 (Silverman et al., 1999)	Mixed population (N = 10 with social anxiety disorder across three groups).
SIQUELAND2005 (Siqueland et al., 2005)	Mixed population (N = 2 with primary social anxiety disorder).

Studies that were ongoing or awaiting assessment

STUDY ID (STUDY CITATION)	REASON FOR EXCLUSION
Studies of adults	
DRKS00000570 (Wiltink et al., 2011)	Ongoing.
DAVIDSON2002 (Davidson, 2002)	Unable to locate full report. Unclear if this is related to a RCT.
DE LA BARQUERA2008 (Ontiveros Sanchez de la Barquera, 2008)	Described as "double-blind", but not clear from the report if this is a randomised trial.
EL REY2008 (D'el Rey et al., 2008)	Brazilian (Portuguese language) trial of group CBT (N = 15) versus waitlist (N = 15).
GULLIVER2009 (Gulliver, 2009)	Unable to locate full report.
KRYLOV1996 (Krylov, 1996)	Unable to locate full report. Unclear if this related to a RCT (of alprozolam and buspirone).
LEE1997 (Lee & Choy, 1997)	Korean trial (Korean language) of two interventions versus waitlist (N = 51).
NCT00128401 (National Institute of Health Clinical Center & National Institute of Mental Health, 2013)	Study completed. Unable to locate full report (compares CBT with or without D-cycloserine).
NCT00182533 (Van Ameringen, Ongoing)	Ongoing.
NCT00184106 (Norwegian University of Science and Technology, 2011)	Study completed. Unable to locate full report (compares paroxetine, cognitive therapy, paroxetine with cognitive therapy, and pill placebo).
NCT00282828 (Pollack, 2012)	Study completed. Unable to locate full report (compares clonazepam, venlafaxine, sertraline, placebo).
NCT01312571 (Carlbring, Ongoing)	Ongoing.
ONTIVEROS1998 (Ontiveros et al., 1998)	Unable to locate full report. Unclear if this related to a RCT (of clonazepam).
PENG2003 (Peng et al., 2003)	Chinese (Chinese language) report with no English-language abstract. Unclear if it is an RCT.
TEJEDOR1996 (Tejedor Calleja & Nicolas Martinez, 1996)	Unable to locate report. Spanish (Spanish language) trial of rational emotive therapy, behavioural procedures, and waitlist (N = 23).
WILLUTZKI2004 (Willutzki et al., 2004;Willutzki et al., 2011)	German (German language) report comparing two forms of CBT (N = 83). Does not appear to include key outcome measures.
YANG (Yang et al., 1999)	Unable to locate full report. Chinese (Chinese language) trial report comparing systematic desensitisation with or without therapist accompaniment (N = 40).
ZHANG2003 (Zhang et al., 2003)	Chinese (Chinese language) trial of paroxetine (N = 40) versus alprazolam (N = 40).
Studies of children and young people	
AHRENS2003 (Ahrens Eipper & Leplow, 2003)	Unable to locate full report.
ANTONA2006 (Antona & Garcia-Lopez, 2008;Antona et al., 2006)	Trial of exposure and cognitive restructuring compared with waitlist (N = 85).
GIL-BERNAL2009 (Gil-Bernal & Hernandez-Guzman, 2009)	Mexican trial (Spanish language) of two interventions (N = 11 participants) versus waitlist (N = 6).
ORTBANDT2009 (Ortbandt & Petermann, 2009)	German (German language) trial of CBT (N = 10) versus control group (N = 9).
RODRIGUEZ2005 (Rodriguez et al., 2005)	Spanish (Spanish language) trial (N = 34).
ROSA-ALCAZAR2009 (Rosa-Alcazar et al., 2009)	Spanish (Spanish language) trial of four interventions and waitlist (N = 77).

References to excluded studies

Ahrens Eipper S, Leplow. Effects of cognitive-behavioral short-time therapy for children with social anxiety. 34th International Meeting of the Society for Psychotherapy Research, June 25-29 2003; Weimar, Germany. pp. 19-20.

Allsopp LF. Clomipramine and diazepam in the treatment of agoraphobia and social phobia in general practice. Current Medical Research and Opinion. 1984;9:64-70.

Antona CJ, Garcia-Lopez LJ. Effects of exposure and cognitive restructuring in social phobia. [Spanish]. Revista Latinoamericana de Psicologia. 2008;40:281-92.

Antona CJ, García-López LJ, Yela JR, Gómez Gómez MA, Salgado A, Delgado C, et al. Effectiveness of exposure and cognitive restructuring in young adults with social anxiety disorder. Psicologia Conductual. 2006;14:183-200.

Barrett PM, Dadds MR, Rapee RM. Family treatment of childhood anxiety: a controlled trial. Journal of Consulting and Clinical Psychology. 1996;64:333-42.

Bernstein GA, Layne AE, Egan EA, Tennison DM. School-based interventions for anxious children. Journal of the American Academy of Child and Adolescent Psychiatry. 2005;44:1118-27.

Bodden DH, Bogels SM, Nauta MH, De HE, Ringrose J, Appelboom C, et al. Child versus family cognitive-behavioral therapy in clinically anxious youth: an efficacy and partial effectiveness study. Journal of the American Academy of Child & Adolescent Psychiatry. 2008;47:1384-94.

Butler G, Cullington A, Munby M, Amies P, Gelder M. Exposure and anxiety management in the treatment of social phobia. Journal of Consulting and Clinical Psychology. 1984;52:642-50.

Carlbring P. Treatment of social phobia over the internet (SOFIE-8). ClinicalTrials.gov Identifier: NCT01312571. Umeå, Sweden Ongoing.

Cassin SE, Rector NA. Mindfulness and the attenuation of post-event processing in social phobia: an experimental investigation. Cognitive Behaviour Therapy. 2011;40:267-78.

Clark DB, Agras WS. The assessment and treatment of performance anxiety in musicians. The American Journal of Psychiatry. 1991;148:598-605.

D'el Rey GJF, Lacava JPL, Cejkinski A, Mello SL. Cognitive-behavioral group treatment in social phobia: 12-week outcome. Revista de Psiquiatria Clinica. 2008;35:79-83.

Davidson JR. Venlafaxine XR in social anxiety disorder. 12th World Congress of Psychiatry, August 24-29, Yokohama, Japan. 2002.

Dogaheh ER, Mohammadkhani P, Dolatshahi B. Comparison of group and individual cognitive-behavioral therapy in reducing fear of negative evaluation. Psychological Reports. 2011;108:955-62.

Donahue CB, Kushner MG, Thuras PD, Murphy TG, Van Demark JB, Adson DE. Effect of quetiapine vs. placebo on response to two virtual public speaking exposures in individuals with social phobia. Journal of Anxiety Disorders. 2009;23:362-68.

Emmelkamp PM, Mersch P, Vissia E, van der Helm M. Social phobia: a comparative evaluation of cognitive and behavioral interventions. Behaviour Research and Therapy. 1985;23:365-9.

Furmark T, Appel L, Michelgård A, Wahlstedt K, Ahs F, Zancan S, et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biological Psychiatry. 2005;58:132-42.

Garcia-Lopez L-J, Olivares J, Turner S, Beidel DC, Albano AM, Sánchez-Meca J. Results at long-term among three psychological treatments for adolescents with generalized social phobia (II): clinical significance and effect size. Psicologia Conductual Revista Internacional de Psicologia Clinica de la Salud. 2002;10:371-85.

Gil-Bernal F, Hernandez-Guzman L. Cognitive-behavioural treatment in Mexican children with social phobia. Anuario de Psicologia. 2009;40:89-104.

Gulliver SBC. CBT and venlafaxine for heavy drinkers with anxiety disorders: 12-month outcomes. Alcoholism: Clinical and Experimental Research. 2009;Conference:June.

Heideman PW. Combining cognitive behavioral therapy with an alcohol intervention to reduce alcohol problems among socially anxious college students. Dissertation Abstracts International: Section B: The Sciences and Engineering. 2008;.69.

Hirshfeld-Becker DR, Masek B, Henin A, Blakely LR, Pollock-Wurman RA, McQuade J, et al. Cognitive behavioral therapy for 4- to 7-year-old children with anxiety disorders: a randomized clinical trial. Journal of Consulting and Clinical Psychology. 2010;78:498-510.

Hofmann SG. Cognitive mediation of treatment change in social phobia. Journal of Consulting and Clinical Psychology. 2004;72:393-99.

Johnston L, Titov N, Andrews G, Spence J, Dear BF. A RCT of a transdiagnostic internet-delivered treatment for three anxiety disorders: examination of support roles and disorder-specific outcomes. PLoS ONE. 2011;6:e28079.

Katzelnick DJ, Kobak K, Greist J, Jefferson J, Mantle J, RC S. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. American Journal of Psychiatry. 1995;152:1368-71.

Kendall PC, Hudson JL, Gosch E, Flannery-Schroeder E, Suveg C. Cognitive-behavioral therapy for anxiety disordered youth: a randomized clinical trial evaluating child and family modalities. Journal of Consulting and Clinical Psychology. 2008;76:282-97.

Kennedy SJ, Rapee RM, Edwards SL, Kennedy SJ. A selective intervention program for inhibited preschool-aged children of parents with an anxiety disorder: effects on current anxiety disorders and temperament. Journal of the American Academy of Child & Adolescent Psychiatry. 2009;48:602-09.

Kobak KA, Taylor LV, Warner G, Futterer R. St. John's wort versus placebo in social phobia: results from a placebo-controlled pilot study. Journal of Clinical Psychopharmacology. 2005;25:51-58.

Krylov V, editor. Pharmacological treatment of social phobia: a controlled study with alprozolam and buspirone: conference abstract. 9th European College of Neuropsychopharmacology Congress 21-25 September; 1996; Amsterdam, The Netherlands. BiomedicalBenzo.

Lee JY, Choy CH. The effects of the cognitive-behavioral and exposure therapy for social phobia. [Korean]. Korean Journal of Counseling & Psychotherapy. 1997;9:35-56.

Liber JM, Van Widenfelt B, Utens E, Ferdinand Rea. No differences between group versus individual treatment of childhood anxiety disorders in a randomised clinical trial. Journal of Child Psychology and Psychiatry and Allied Disciplines. 2008;49:886-93.

Manassis K, Mendlowitz SL, Scapillate D, Avery D, Fiksenbaum L, Freire M, et al. Group and individual cognitive-behavioral therapy for childhood anxiety disorders: a randomized trial. Journal of the American Academy of Child and Adolescent Psychiatry. 2002;41:1423-30.

Marks IM, Kenwright M, McDonough M, Whittaker M, Mataix-Cols D. Saving clinicians' time by delegating routine aspects of therapy to a computer: a randomized controlled trial in phobia/panic disorder. Psychological Medicine. 2004;34:9-17.

Mersch PP. The treatment of social phobia: the differential effectiveness of exposure in vivo and an integration of exposure in vivo, rational emotive therapy and social skills training. Behaviour Research and Therapy. 1995;33:259-69.

Mortberg E, Karlsson A, Fyring C, Sundin O. Intensive cognitive-behavioral group treatment (CBGT) of social phobia: A randomized controlled study. Journal of Anxiety Disorders. 2006;20:646-60.

National Institute of Health Clinical Center, National Institute of Mental Health. Use of an antibiotic as an enhancer for the treatment of social phobia. ClinicalTrials.gov Identifier: NCT00128401. US 2013.

Neubauer K, Auer Mv, Murray E, Petermann F, Helbig-Lang S, Gerlach AL. Internet-delivered attention modification training as a treatment for social phobia: a randomized controlled trial. Behaviour Research and Therapy. 2013;51:87-97.

Norton PJ, Barrera TL. Transdiagnostic versus diagnosis-specific cbt for anxiety disorders: a preliminary randomized controlled noninferiority trial. Depression and Anxiety. 2012;29:874-82.

Norwegian University of Science and Technology. RCT of cognitive therapy, paroxetine, combined CT and paroxetine and placebo. ClinicalTrials.gov Identifier: NCT00184106. Norway 2011.

Olivares J, Garcia-Lopez LJ, Beidel DC, Turner SM, Albano AM, Hidalgo MD. Results at long-term among three psychological treatments for adolescents with generalized social phobia (I): statistical significance. Psicologia Conductual Revista Internacional de Psicologia Clinica de la Salud. 2002;10:147-64.

Ontiveros A, Costilla A, Rojas A, Diaz R, editors. Clonazepam long-term efficacy in social phobia. 151st Annual Meeting of the American Psychiatric Association; 1998 30th May - 4th June; Toronto, Ontario, Canada. BiomedicalBenzo.

Ontiveros Sanchez de la Barquera JA. Double-blind controlled study with clonazapam and placebo in social anxiety disorder. Salud Mental. 2008;31:299-306.

Ortbandt C, Petermann U. Effects of a cognitive-behavioral training program for children with social anxiety. [German]. Kindheit und Entwicklung. 2009;18:21-29.

Peng C, Yan L, Ma X, Wu W. Effect of group therapy on social anxiety of college students. Chinese Mental Health Journal. 2003;17:229-34.

Pollack MH. Improving treatment outcomes in pharmacotherapy of generalized social anxiety disorder: ClinicalTrials.gov Identifier: NCT00282828. Massachusetts General Hospital 2012.

Randall CL, Johnson MR, Thevos AK, Sonne SC, Thomas SE, Willard SL, et al. Paroxetine for social anxiety and alcohol use in dual-diagnosed patients. Depression and Anxiety. 2001;14:255-62.

Ravindran LN, Kim DS, Letamendi AM, Stein MB. A randomized controlled trial of atomoxetine in generalized social anxiety disorder. Journal of Clinical Psychopharmacology. 2009;29:561-64.

Rodriguez JO, Alcazar AIR, Rodriguez JAP. Early detection and treatment of adolescents with generalized social phobia. [Spanish]. Psicothema. 2005;17:1-8.

Rosa-Alcazar AI, Olivares-Olivares PJ, Olivares J. The role of non-specific effects in the psychological treatment of adolescents with social phobia. Anuario de Psicologia. 2009;40:43-61.

Schneider AJ, Mataix-Cols D, Marks IM, Bachofen M, Schneider AJ, Mataix-Cols D, et al. Internet-guided self-help with or without exposure therapy for phobic and panic disorders. Psychotherapy & Psychosomatics. 2005;74:154-64.

Shortt AL, Barrett PM, Fox TL. Evaluating the FRIENDS program: a cognitive-behavioral group treatment for anxious children and their parents. Journal of clinical child psychology. 2001;30:525-35.

Silverman WK, Kurtines WM, Ginsburg GS, Weems CF, Rabian B, Serafini LT. Contingency management, self-control, and education support in the treatment of childhood phobic disorders: a randomized clinical trial. Journal of Consulting and Clinical Psychology. 1999;67:675-87.

Siqueland L, Rynn M, Diamond GS. Cognitive behavioral and attachment based family therapy for anxious adolescents: phase I and II studies. Journal of Anxiety Disorders. 2005;19:361-81.

Solyom CS. Phenelzine and exposure in the treatment of phobias. Biological Psychiatry. 1981;16:239-47.

Tauscher J, Kielbasa W, Iyengar S, Vandenhende F, Peng X, Mozley D, et al. Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder. European Neuropsychopharmacology. 2010;20:80-87.

Taylor CT, Alden LE. Safety behaviors and judgmental biases in social anxiety disorder. Behaviour Research and Therapy. 2010;48:226-37.

Taylor S, Woody S, Koch W, McLean P, Paterson R, Anderson K. Cognitive restructuring in the treatment of social phobia: efficacy and mode of action. Behavior Modification. 1997;21:487-511.

Tejedor Calleja A, Nicolas Martinez Ld. Social skills training: a comparative study. [Spanish]. Analisis y Modificacion de Conducta. 1996;22:709-27.

Turner SM, Beidel D, Jacob R. Social phobia: a comparison of behavior therapy and atenolol. Journal of Consulting and Clinical Psychology. 1994;62:350-58.

Tyrer P, Candy J, Kelly D. A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety. Psychopharmacologia. 1973;32:237-54.

Van Ameringen M. Sertraline in generalized social phobia with co-occurring anxiety and mood disorders. ClinicalTrials.gov Identifier: NCT00182533. US Ongoing.

Van Ameringen M, Mancini C, Oakman J, Walker J, Kjernisted K, Chokka P, et al. Nefazodone in the treatment of generalized social phobia: a randomized, placebo-controlled trial. Journal of Clinical Psychiatry. 2007;68:288-95.

Van Vliet I. Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study. Journal of Clinical Psychiatry. 1997;58:164-68.

Versiani MN. Double-blind placebo controlled trial with bromazepam in social phobia. Jornal Brasileiro de Psiquiatria. 1997;46:167-71.

Willutzki U, Neumann B, Haas H, Koban C, Schulte D. Psychotherapy for social phobia: cognitive behavioral therapy in comparison to a combined resource-oriented approach. A randomized controlled interventional trial. Zeitschrift fur Klinische Psychologie und Psychotherapie. 2004;33:42-50.

Willutzki U, Teismann T, Schulte D. Psychotherapy for social phobia. Changes in well-being after cognitive behavioral therapy in comparison to a combined resource-oriented approach. [German]. Zeitschrift fur Klinische Psychologie und Psychotherapie: Forschung und Praxis. 2011;40:53-58.

Wiltink J, Ruckes C, Haselbacher A, Canterino M, Leichsenring F, Joraschky P, et al. Transfer of manualized Short Term Psychodynamic Psychotherapy (STPP) for social phobia into clinical practice: study protocol for a cluster-randomised controlled trial. Trials. 2011;12:142.

Yang K, Yang M, Liu H. Comparative study of the effects of accompanied systemic desensitization in the treatment of social phobia. [Chinese]. Chinese Mental Health Journal. 1999;13:238-39.

Zhang G, Wei HY, Zeng ZX, et al. A double-blinded study of paroxetine and alprazolam in the treatment of social phobia. Shandong Archives of Psychiatry. 2003;16:144-46.

Zhang Y, Yang D, Xiao Z, Fong Y, Zhang H, Zhou H, et al. The role of Taoist cognitive psychotherapy in the treatment of anxiety disorder. [Chinese]. Chinese Mental Health Journal. 2000;14.